CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (Nasdaq: ALKS) today announced the initiation of a phase 1 clinical study of AIR® parathyroid hormone (AIR PTH [1-34]) in healthy volunteers. AIR PTH is an inhaled formulation of Eli Lilly and Company's recombinant parathyroid hormone, FORTEO® (teriparatide (rDNA origin) injection), based on Alkermes' proprietary AIR® pulmonary technology. The phase 1 study will assess the safety, tolerability and pharmacokinetics of AIR PTH in healthy postmenopausal women.
